Crowdfunding campaign for cancer vaccine

A crowdfunding campaign started on October 20 in Paris to support the UCPVax program, a therapeutic cancer vaccine project developed from public research in Besançon, has seen a "very encouraging" response, according to the Besançon University Hospital Center (CHU). Nearly 16,000 euros have been raised on the ucpvax.org platform within one week.

Focus on difficult-to-treat cancers

The campaign reflects the hopes and expectations that UCPVax generates among patients and their families, especially those dealing with particularly difficult-to-treat cancers such as glioblastoma and lung cancer. The goal now is to continue research to confirm the vaccine’s therapeutic potential and advance the next stages of its clinical development.

Clinical trial details available

The CHU explains that the list of clinical trials, both ongoing and in preparation, is available on the site’s page: ucpvax.org/essais-cliniques/. It emphasizes that when a trial is open, participation is "subject to inclusion and exclusion criteria defined by its protocol," including the type and stage of cancer, treatments already received, and general health status. "Therefore, not all patients can necessarily participate," it is stated.

Updating information for participants

The CHU invites patients and their families to follow the information published on the page, where the status of the clinical trials and their participation criteria are intended to be detailed and updated. UCPVax needs the support of "as many people as possible to continue its development," according to the CHU, which states that the coming years will be "decisive in confirming the results obtained" and allow, if the data justify it, "to consider the next steps toward a possible access to the treatment." For more information on the program and to support it, visit ucpvax.org.